Login to Complete an Application or to Access Judging Panel
Introduction
OVERALL - 2.5%
- DOES NOT MEET EXPECTATIONS - Ineffective introduction. Failed to provide concise business proposition.
- MOVING TOWARD EXPECTATIONS - Adequate introduction. Eventually conveyed invention's purpose and value. Should be more crisp.
- MEETS EXPECTATIONS - Effective introduction. Conveyed invention’s purpose and value.
- EXCEEDS EXPECTATIONS - Exceptional introduction. Compellingly conveys invention’s purpose and value.
Product / Solution
TECHNICAL MATURITY - 5%
- DOES NOT MEET EXPECTATIONS - Minimal or no data obtained.
- MOVING TOWARD EXPECTATIONS - Proof of concept experiments performed. Feasibility testing on-going.
- MEETS EXPECTATIONS - Strong dataset, e.g. two animal models. Substantial product development still required.
- EXCEEDS EXPECTATIONS - Data package sufficient to share with regulatory/reimbursement authorities. Ready for market or clinical testing.
PRODUCT DEVELOPMENT RISK - 5%
- DOES NOT MEET EXPECTATIONS - Massive product development risk. Still in conceptual stage or unclear development plan.
- MOVING TOWARD EXPECTATIONS - Significant product development risk remains. Development plans insufficiently thorough.
- MEETS EXPECTATIONS - Product development risk medium to low. Remaining development well planned.
- EXCEEDS EXPECTATIONS - Product development risk minimal. Design, engineering and manufacturing issues resolved.
COMPETITIVE ADVANTAGE - 5%
- DOES NOT MEET EXPECTATIONS - No evidence of competitive analysis. Undifferentiated product.
- MOVING TOWARD EXPECTATIONS - Partial competitive analysis. Weak product differentiation.
- MEETS EXPECTATIONS - Thorough competitive analysis. Strongly differentiated product. Accounted for most substitutes.
- EXCEEDS EXPECTATIONS - Persuasive competitive analysis. Highly differentiated, accounted for all substitutes, provides novel solution.
Intellectual Property
OVERALL - 10%
- DOES NOT MEET EXPECTATIONS - No evidence of defensible IP or barriers to competition.
- MOVING TOWARD EXPECTATIONS - Unclear or flawed IP protection and/or ownership. No barriers to competition.
- MEETS EXPECTATIONS - Evidence of meaningful IP available to protect the invention. Potential other barriers to competition.
- EXCEEDS EXPECTATIONS - Evidence of a strong portfolio providing barriers to competition, e.g. multiple patents issued or allowed. Other barriers to competition.
Market Segment
DEFINITION - 4%
- DOES NOT MEET EXPECTATIONS - Undefined market segment.
- MOVING TOWARD EXPECTATIONS - Somewhat defined market segment.
- MEETS EXPECTATIONS - Defined market segment.
- EXCEEDS EXPECTATIONS - Highly defined market segment.
SIZE IN DOLLARS - 3%
- DOES NOT MEET EXPECTATIONS - Market segment as a whole < $5M per year.
- MOVING TOWARD EXPECTATIONS - Market segment as a whole between $5M and $50M per year.
- MEETS EXPECTATIONS - Market segment as a whole between $50M and $250M per year.
- EXCEEDS EXPECTATIONS - Market segment as a whole > $250M per year.
GROWTH - 3%
- DOES NOT MEET EXPECTATIONS - Market segment growth negative or zero.
- MOVING TOWARD EXPECTATIONS - Market segment growth modestly positive.
- MEETS EXPECTATIONS - Market segment growth robust.
- EXCEEDS EXPECTATIONS - Market segment growth explosive.
Human Impact
PER PATIENT IMPACT - 5%
- DOES NOT MEET EXPECTATIONS - Moderate quality of life enhancement potential vs. status quo.
- MOVING TOWARD EXPECTATIONS - Significant quality of life enhancement potential vs. status quo.
- MEETS EXPECTATIONS - Life-extending potential vs. status quo.
- EXCEEDS EXPECTATIONS - Life-saving potential vs. status quo.
NUMBER OF PATIENTS - 5%
- DOES NOT MEET EXPECTATIONS - Annual global patients total less than 1000.
- MOVING TOWARD EXPECTATIONS - Annual global patients total between 1000 and 10,000.
- MEETS EXPECTATIONS - Annual global patients total between 10,000 and 100,000 per year.
- EXCEEDS EXPECTATIONS - Annual global patients total more than 100,000 per year.
TIME TO IMPACT - 5%
- DOES NOT MEET EXPECTATIONS - On the market or in clinical trial in more than 10 years.
- MOVING TOWARD EXPECTATIONS - On the market or in clinical trial between 5 and 10 years.
- MEETS EXPECTATIONS - On the market or in clinical trial between 3 and 5 years.
- EXCEEDS EXPECTATIONS - On the market or in clinical trial in less than 3 years.
Inventor Disposition
INVENTOR ENGAGEMENT - 3%
- DOES NOT MEET EXPECTATIONS - Inventor seems reluctant or ambivalent. No evidence of inventor-led commercialization progress on this innovation.
- MOVING TOWARD EXPECTATIONS - Inventor seems engaged. No evidence of inventor- led commercialization progress on this innovation.
- MEETS EXPECTATIONS - Inventor is credibly engaged. Some evidence of inventor-led commercialization progress on this innovation.
- EXCEEDS EXPECTATIONS - Inventor is enthusiastically engaged. Significant evidence of inventor-led commercialization progress on this innovation.
INDUSTRY CONNECTIONS - 3%
- DOES NOT MEET EXPECTATIONS - Team members unknown in the industry. Team has zero personal commercial connections.
- MOVING TOWARD EXPECTATIONS - Team members mostly unknown in the industry. Team has a few personal commercial connections.
- MEETS EXPECTATIONS - Team members are known in the industry. Team has many personal commercial connections.
- EXCEEDS EXPECTATIONS - Team members are highly recognized in the industry. Team has many valuable personal commercial connections.
COMMERCIALIZATION EXPERIENCE - 4%
- DOES NOT MEET EXPECTATIONS - Inventor has no commercialization or startup experience. Has not identified business teammates or advisors.
- MOVING TOWARD EXPECTATIONS - Inventor has some commercialization or startup experience. Has identified, but not yet recruited business teammates or advisors.
- MEETS EXPECTATIONS - Inventor has relevant commercialization or startup experience. Has recruited a least one business teammate or advisor.
- EXCEEDS EXPECTATIONS - Inventor has deep commercialization or startup experience. Has recruited multiple high-caliber teammates or advisors.
Budget and Plan
BUDGET - 3%
- DOES NOT MEET EXPECTATIONS - Incomplete budget projections.
- MOVING TOWARD EXPECTATIONS - Unrealistic budget projections.
- MEETS EXPECTATIONS - Credible budget projections.
- EXCEEDS EXPECTATIONS - Convincing budget projections.
ADDITIONAL RESOURCES - 3%
- DOES NOT MEET EXPECTATIONS - Fails to recognize additional resources required.
- MOVING TOWARD EXPECTATIONS - Partially recognizes additional resources required. Provides no strategy to obtain them.
- MEETS EXPECTATIONS - Recognizes additional resources required, and provides credible strategy to obtain them.
- EXCEEDS EXPECTATIONS - Thoroughly recognizes additional resources required, and provides compelling strategy to obtain them.
OUTLINE & TIMELINE - 4%
- DOES NOT MEET EXPECTATIONS - Unclear outline. No timeline
- MOVING TOWARD EXPECTATIONS - Clear outline. Unrealistic timeline
- MEETS EXPECTATIONS - Detailed outline. Somewhat realistic timeline
- EXCEEDS EXPECTATIONS - Highly detailed outline. Realistic timeline
Regulatory Risk
AWARENESS OF REGULATORY, COMPLIANCE, LEGAL ISSUES - 5%
- DOES NOT MEET EXPECTATIONS - Failed to demonstrate knowledge of relevant regulatory, compliance and legal issues.
- MOVING TOWARD EXPECTATIONS - Partially demonstrates knowledge of relevant regulatory, compliance and legal issues.
- MEETS EXPECTATIONS - Adequately demonstrates knowledge of relevant regulatory, compliance and legal issues.
- EXCEEDS EXPECTATIONS - Persuasively demonstrates knowledge of relevant regulatory, compliance and legal issues.
PLAN FOR REGULATORY, COMPLIANCE, LEGAL ISSUES - 5%
- DOES NOT MEET EXPECTATIONS - Fails to provide plan to address regulatory issues.
- MOVING TOWARD EXPECTATIONS - Provides a plan that partially addresses regulatory issues.
- MEETS EXPECTATIONS - Provides clear plan to address regulatory issues.
- EXCEEDS EXPECTATIONS - Provides a compelling plan to address regulatory issues.
Grubstake Alignment
MISSION ALIGNMENT - 5%
- DOES NOT MEET EXPECTATIONS - Not aligned with Gates Center’s regenerative medicine mission. Does not advance current medical practice.
- MOVING TOWARD EXPECTATIONS - Somewhat aligned with Gates Center’s regenerative medicine mission. Slightly advances current medical practice.
- MEETS EXPECTATIONS - Aligned with Gates Center’s regenerative medicine mission. Moderately advances current medical practice.
- EXCEEDS EXPECTATIONS - Highly aligned with Gates Center’s regenerative medicine mission. Significantly advances current medical practice.
PROCESS DEVELOPMENT - 5%
- DOES NOT MEET EXPECTATIONS - Not a candidate for the Gates Biomanufacturing Facility.
- MOVING TOWARD EXPECTATIONS - Possible to do product development at the Gates Biomanufacturing Facility.
- MEETS EXPECTATIONS - Biologic or cell therapy that can be manufactured at the Gates Biomanufacturing Facility.
- EXCEEDS EXPECTATIONS - Is currently (or soon will be) manufactured at the Gates Biomanufacturing Facility.
LEVERAGE POTENTIAL - 5%
- DOES NOT MEET EXPECTATIONS - Grant would not address a finance gap and will not be leveraged with additional funding. Does not create an inflection point.
- MOVING TOWARD EXPECTATIONS - Unclear if Grant would fill a finance gap. Likely no funding leverage. May not create an inflection point.
- MEETS EXPECTATIONS - Grant would fill a finance gap and could be leveraged with additional funding. Likely to create an inflection point.
- EXCEEDS EXPECTATIONS - Clear evidence that the Grant would fill an identified finance gap and the additional funding leverage is secured. Will create an inflection point.
Presentation Quality
QUALITY OF PROSE - 1%
- DOES NOT MEET EXPECTATIONS - Poorly written. Very difficult to understand or follow logic. Spelling or grammatical errors.
- MOVING TOWARD EXPECTATIONS - Reasonably well-written. Sometimes difficult to follow logic. Few spelling or grammatical errors.
- MEETS EXPECTATIONS - Effectively written. Convincing, easy to follow logic. No spelling or grammatical errors.
- EXCEEDS EXPECTATIONS - Clearly and persuasively written. Compelling logical arguments. No spelling or grammatical errors.
DATA QUALITY & ATTRIBUTION - 1.5%
- DOES NOT MEET EXPECTATIONS - Poorly supported by data. Little to no attribution of sources.
- MOVING TOWARD EXPECTATIONS - Partially supported by data. Some attribution of sources.
- MEETS EXPECTATIONS - Credibly supported by data. Data sources are properly attributed.
- EXCEEDS EXPECTATIONS - Persuasively supported by meaningful data. Fully attributed data greatly enhances investment thesis.
Share